Q4 2025
Released May 29, 2025, before the open
10-K filed May 29, 2025, 59 days after period end · 0001764013-25-000092
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$106.45M-$106.45M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$110,637,000N/M
Free Cash Flowderived-$110,838,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$106.45M | -$75.32M | -$59.43M | -$47.17M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR